Basgenbio is a clinico-genomic cohort-based R&D company with K-Biobank, which contains blood samples from 156,000 subjects, along with their clinical and lifestyle information, with a maximum follow-up period of 18 years. To this date, 23.4% of the subjects have been diagnosed spanning diverse disease categories. Notably, we have 8,662 cancer and 75,424 major chronic disease events including hypertension, CVD, and T2DM.
Drawing on our experience in building an exclusive cohort data, Basgenbio also work on establishing an aging-related biobank (for sarcopenia, osteoporosis, osteoarthritis, rheumatoid arthritis, etc.) and a rare disease biobank (for retinitis pigmentosa, age-related macular degeneration, diabetic macular edema, etc.) in collaboration with pharmaceutical companies, universities, and national associations.
With the remaining blood samples from 156K subjects, Basgenbio plans to conduct additional multi-omics tests to ultimately build a clinico-omics cohort data platform.
Drawing on our experience in building an exclusive cohort data, Basgenbio also work on establishing an aging-related biobank (for sarcopenia, osteoporosis, osteoarthritis, rheumatoid arthritis, etc.) and a rare disease biobank (for retinitis pigmentosa, age-related macular degeneration, diabetic macular edema, etc.) in collaboration with pharmaceutical companies, universities, and national associations.
With the remaining blood samples from 156K subjects, Basgenbio plans to conduct additional multi-omics tests to ultimately build a clinico-omics cohort data platform.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Main Therapeutic Focus:
Other
Lead Product in Development:
K-Biobank: A core asset of Basgenbio’s clinico-genomic cohort database
Aging-Related Biobank (for sarcopenia, osteoporosis, osteoarthritis, rheumatoid arthritis, etc.)
Rare Disease Biobank (for retinitis pigmentosa, age-related macular degeneration (AMD), diabetic macular edema (DME), etc.)
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
